

Acarix Q1 2023 - Progress in the making

Redeye leaves its comments on Acarix following the company's Q1 2023 report. The report contained no significant surprises, and we largely maintain our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Acarix Q1 2023 - Progress in the making](#)